<p>2025 年 10 月 09 日- 上午 09:20</p>
<ul>
<li>聘请战略商业发展顾问公司以支持新业务发展活动</li>
<li>Lexaria 获得 4 项新专利</li>
</ul>
<p>Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)（以下简称 “公司” 或 “Lexaria”），作为全球药物递送平台的创新者，欣然提供以下战略业务更新。</p>
<p>多年来，Lexaria 一直在验证其专利的 DehydraTECH 技术在制药行业多个领域的适用性。同时，Lexaria 利用历史上有限的内部资源，尽可能追求更多的商业机会，同时承认 DehydraTECH 在制药应用开发的早期阶段。Lexaria 的研发验证项目已经确定了几个感兴趣的制药领域，包括但不限于：糖尿病控制和减肥、 hypertension、癫痫、抗病毒应用和激素替代。</p>
<p>Lexaria 很高兴地宣布，现已通过聘请一家全球生命科学商业发展顾问公司来增强其内部主导的业务发展活动，以帮助识别和追求全球范围内的额外合作商业机会。根据该协议，针对制药和生物技术行业的新外联活动正在进行中。由于许可和合作讨论的敏感战略性质，相关方的详细信息将保持机密。</p>
<p>支持这一战略外联扩展及相关关键研发的资源，已通过 Lexaria 最近完成的股权融资获得，该融资在优良条件下筹集了 400 万美元的总收入。在此融资之前，公司现有的运营和持续的研发项目已完全资助至 2025 年底。额外的资本是为了推进和执行 2026 年重要的支持性新研发扩展活动的计划。</p>
<p>大多数研发项目需要几个月的准备时间，包括研究设计、监管批准以及与第三方供应商签订具有约束力的合同。考虑到这一点，如果公司没有获得这些新资金，2026 年上半年将缺乏重要的新研发项目及其对公司业务发展的潜在影响。因此，企业融资决策是公司更广泛战略目标的重要组成部分。</p>
<p>研发项目与制药和生物技术行业的商业和战略联系的建立与加强是相辅相成的。即使成功达成合作协议，通常也仅限于狭义定义的研究领域，Lexaria 的短期经济利益也可能仅限于这些共同感兴趣的领域。然而，由于其广泛的平台性质，Lexaria 的 DehydraTECH 技术在许多不同领域显示出优势和改进，管理层相信公司现在已准备好通过聘请的全球生命科学商业发展公司进行扩展外联。</p>
<p>凭借新的财务资源，Lexaria 现在能够在冬季及 2026 年上半年推进其业务发展和研发项目。一旦最终决策做出并建立预算，公司将提供关于其令人兴奋的战略研发计划的更多更新。</p>
<p>在此期间，我们还预计将获得公司在 GLP-1 领域的重要 1b 期澳大利亚研究的最终结果，预计将证明使用 DehydraTECH 处理的某些行业领先的 GLP-1 及其补充药物的患者安全性和有效性。</p>
<p>此外，Lexaria 很高兴地宣布已获得 4 项新专利，继续扩展我们已经相当可观的知识产权组合。这些专利支持我们战略研发项目的巨大价值，因为它们涵盖了糖尿病、高血压、癫痫、抗病毒治疗等领域的广泛治疗应用。</p>
<p>新专利总结如下：</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>已授予</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>专利号</strong></td>
<td><strong>专利证书授予日期</strong></td>
<td><strong>专利</strong></td>
</tr>
<tr>
<td><strong>家族</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AU 2024202475</td>
<td>2025 年 7 月 24 日</td>
<td>#24 治疗癫痫的组合物和方法</td>
</tr>
<tr>
<td>US 12,397,042</td>
<td>2025 年 8 月 26 日</td>
<td>#27 治疗糖尿病的组合物和方法</td>
</tr>
<tr>
<td>EP 3858364</td>
<td>2025 年 9 月 17 日</td>
<td>#1 含有脂溶性活性成分的食品和饮料组合物及其使用方法</td>
</tr>
<tr>
<td>AU 2023200736</td>
<td>2025 年 10 月 2 日</td>
<td>#18 增强抗病毒剂递送的组合物和方法</td>
</tr>
</tbody>
</table>
<p>总之，最近融资的收益为 Lexaria 提供了增强我们 2026 年企业业务发展和战略研发项目的机会，以及继续扩展和加强我们的专利组合。这些举措旨在为 Lexaria 提供更多的 “进攻机会” 和提升股东价值的机会。</p>
<p><strong>关于 Lexaria Bioscience Corp.及 DehydraTECH</strong></p>
<p>DehydraTECH™是 Lexaria 的专利药物递送配方和处理平台技术，改善了各种药物通过口服递送进入血液的方式。DehydraTECH 已多次证明能够提高生物吸收率、减少副作用，并更有效地穿越血脑屏障递送某些药物。Lexaria 运营着一个获得许可的内部研究实验室，并拥有 54 项已授予的专利和其他正在全球申请的专利的强大知识产权组合。有关更多信息，请访问 www.lexariabioscience.com。</p>
<p><strong>关于前瞻性声明的警告</strong></p>
<p>本新闻稿包含根据适用证券法定义的前瞻性声明。这些声明可能通过诸如 “预期”、“如果”、“相信”、“计划”、“估计”、“期望”、“打算”、“可能”、“能够”、“应该”、“将会” 等类似词语来识别。本新闻稿中的前瞻性声明包括但不限于公司关于拟定用途的声明，涉及融资所得的使用、公司预期的 2026 年研发和业务发展计划，以及公司开展研究计划、获得监管批准或补助，或从任何研究或研究中获得积极效果或结果的能力。这些前瞻性声明是基于当前信息反映公司最佳判断的估计，涉及多种风险和不确定性，无法保证公司将实际实现这些前瞻性声明中披露的计划、意图或期望。因此，您不应对这些前瞻性声明过度依赖。可能导致实际结果与公司估计结果存在重大差异的因素包括但不限于市场及其他条件、政府监管和监管批准、管理和维持增长、负面宣传的影响、诉讼、竞争、科学发现、专利申请和批准过程、使用 DehydraTECH 技术的产品测试或使用可能产生的潜在不利影响、公司维持现有合作关系并实现其利益的能力、与疫情相关或其他原因导致的计划研发的延迟或取消，以及公司在其公开公告和定期向美国证券交易委员会 EDGAR 提交的文件中不时可能识别的其他因素。公司仅为读者提供第三方网站的链接，且对第三方网站信息的全面性、准确性或及时性不承担任何责任。无法保证 Lexaria 所设想的专利及专利申请技术的任何用途、益处或优势将以任何方式或部分实现。本声明中的任何内容均未经过食品药品监督管理局（FDA）的评估。与 Lexaria 相关的产品并不旨在诊断、治疗、治愈或预防任何疾病。本声明中包含的任何前瞻性声明仅在本声明日期有效，公司明确不承担更新本声明中包含的任何前瞻性声明或第三方网站链接的义务，无论是由于任何新信息、未来事件、情况变化或其他原因，法律另有要求的情况除外。</p>
<p><strong>投资者联系：</strong></p>
<p><strong>George Jurcic - 投资者关系负责人</strong></p>
<p>ir@lexariabioscience.com</p>
<p>电话：250-765-6424，分机 202</p>
<p><strong>来源：</strong> Lexaria Bioscience Corp.</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTA4NDg4Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTA4NDg4Mg"/></p>

LEXX

<p>Lexaria Bioscience Corp.（纳斯达克代码：LEXX）已聘请一家全球生命科学咨询公司，以增强其业务发展工作，此举是在获得四项新专利之后。该公司通过股权融资筹集了 400 万美元，以支持其研发项目和在制药领域的战略拓展。Lexaria 的 DehydraTECH 技术旨在改善在包括糖尿病和抗病毒治疗等多个治疗领域的药物递送。新的资金将使公司能够推进其在 2026 年前的各项计划，并预计将对其战略研发计划和正在进行的研究进行更新</p>

<p>10/09/2025 - 09:20 AM</p>
<div class="lb-trans"><p>2025 年 10 月 09 日- 上午 09:20</p>
</div><ul>
<li>Strategic Business Development Advisory Firm Engaged To Support New Business Development Activities</li>
<li>Lexaria Awarded 4 New Patents</li>
</ul>
<div class="lb-trans"><ul>
<li>聘请战略商业发展顾问公司以支持新业务发展活动</li>
<li>Lexaria 获得 4 项新专利</li>
</ul>
</div><p>Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the &#34;Company&#34; or &#34;Lexaria&#34;), a global innovator in drug delivery platforms is pleased to provide the following strategic business update.</p>
<div class="lb-trans"><p>Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)（以下简称 “公司” 或 “Lexaria”），作为全球药物递送平台的创新者，欣然提供以下战略业务更新。</p>
</div><p>For several years, Lexaria has been validating the applicability of its patented DehydraTECH technology across a number of sectors within the pharmaceutical industry. In parallel, Lexaria has pursued as many business opportunities as possible using historically limited internal resources, while acknowledging the early stages of DehydraTECH development for pharmaceutical applications. Lexaria's R&amp;D validation programs have already identified several pharmaceutical areas of interest including, but not limited to: treatments for diabetes control and weight loss, hypertension, seizure disorders, anti-viral applications and hormone replacement.</p>
<div class="lb-trans"><p>多年来，Lexaria 一直在验证其专利的 DehydraTECH 技术在制药行业多个领域的适用性。同时，Lexaria 利用历史上有限的内部资源，尽可能追求更多的商业机会，同时承认 DehydraTECH 在制药应用开发的早期阶段。Lexaria 的研发验证项目已经确定了几个感兴趣的制药领域，包括但不限于：糖尿病控制和减肥、 hypertension、癫痫、抗病毒应用和激素替代。</p>
</div><p>Lexaria is pleased to announce it has now augmented its ongoing internally led business development activities by hiring a global life science business development advisory firm to help identify and pursue additional collaborative business opportunities around the world. Under the terms of that engagement, new outreach activities to the pharmaceutical and biotechnology sectors are underway. Due to the sensitive strategic nature of licensing and partnering discussions, details of the parties involved will remain confidential.</p>
<div class="lb-trans"><p>Lexaria 很高兴地宣布，现已通过聘请一家全球生命科学商业发展顾问公司来增强其内部主导的业务发展活动，以帮助识别和追求全球范围内的额外合作商业机会。根据该协议，针对制药和生物技术行业的新外联活动正在进行中。由于许可和合作讨论的敏感战略性质，相关方的详细信息将保持机密。</p>
</div><p>The resources permitting this expansion of strategic outreach, and key supportive R&amp;D related thereto, have been made available through Lexaria's recently completed equity financing which yielded gross proceeds of $4.0 million on excellent terms. Prior to that financing, the Company's existing operations and ongoing R&amp;D programs were fully funded through the end of 2025. The additional capital was required in order to advance and execute plans for important supportive new R&amp;D expansion activities into 2026.</p>
<div class="lb-trans"><p>支持这一战略外联扩展及相关关键研发的资源，已通过 Lexaria 最近完成的股权融资获得，该融资在优良条件下筹集了 400 万美元的总收入。在此融资之前，公司现有的运营和持续的研发项目已完全资助至 2025 年底。额外的资本是为了推进和执行 2026 年重要的支持性新研发扩展活动的计划。</p>
</div><p>Most R&amp;D projects require several months' lead time for activities including study design, regulatory approvals, and entry into binding contracts with third-party vendors. With this in mind, had the Company not obtained these new funds, the first half of 2026 would have been devoid of vital new R&amp;D programs and their attendant potential for corporate business development. Corporate finance decisions are thus an integral part of the Company's broader strategic goals.</p>
<div class="lb-trans"><p>大多数研发项目需要几个月的准备时间，包括研究设计、监管批准以及与第三方供应商签订具有约束力的合同。考虑到这一点，如果公司没有获得这些新资金，2026 年上半年将缺乏重要的新研发项目及其对公司业务发展的潜在影响。因此，企业融资决策是公司更广泛战略目标的重要组成部分。</p>
</div><p>R&amp;D programs evolve hand-in-hand with building and strengthening business and strategic connections in the pharmaceutical and biotechnology industries. Even when successful collaboration agreements are reached, they are often limited in scope to narrowly defined areas of study and the short-term economic benefits to Lexaria might also be limited to those areas of mutual interest. However, because of its broad platform nature, Lexaria's DehydraTECH technology has evidenced advantages and improvements in many different sectors and management believes the Company is now ready for the expanded outreach made possible through the engagement of the noted global life science business development firm.</p>
<div class="lb-trans"><p>研发项目与制药和生物技术行业的商业和战略联系的建立与加强是相辅相成的。即使成功达成合作协议，通常也仅限于狭义定义的研究领域，Lexaria 的短期经济利益也可能仅限于这些共同感兴趣的领域。然而，由于其广泛的平台性质，Lexaria 的 DehydraTECH 技术在许多不同领域显示出优势和改进，管理层相信公司现在已准备好通过聘请的全球生命科学商业发展公司进行扩展外联。</p>
</div><p>Empowered with new financial resources, Lexaria is now able to advance its business development and R&amp;D programs through the winter and into the first half of calendar 2026. Once final decisions have been made and budgets have been established, the Company will provide additional updates on its exciting strategic R&amp;D plans.</p>
<div class="lb-trans"><p>凭借新的财务资源，Lexaria 现在能够在冬季及 2026 年上半年推进其业务发展和研发项目。一旦最终决策做出并建立预算，公司将提供关于其令人兴奋的战略研发计划的更多更新。</p>
</div><p>During this period, we also anticipate the final results from the Company's important Phase 1b Australian study in the GLP-1 sector, expected to evidence patient safety and efficacy with DehydraTECH processing of certain industry-leading GLP-1 and complementary drugs marketed today.</p>
<div class="lb-trans"><p>在此期间，我们还预计将获得公司在 GLP-1 领域的重要 1b 期澳大利亚研究的最终结果，预计将证明使用 DehydraTECH 处理的某些行业领先的 GLP-1 及其补充药物的患者安全性和有效性。</p>
</div><p>In addition, Lexaria is pleased to announce that it has been awarded 4 new patents, continuing to build upon our already significant intellectual property portfolio. These patents support the immense value of our strategic R&amp;D programs as they cover broad therapeutic applications within the fields of diabetes, hypertension, seizure disorders, antiviral treatments, and more.</p>
<div class="lb-trans"><p>此外，Lexaria 很高兴地宣布已获得 4 项新专利，继续扩展我们已经相当可观的知识产权组合。这些专利支持我们战略研发项目的巨大价值，因为它们涵盖了糖尿病、高血压、癫痫、抗病毒治疗等领域的广泛治疗应用。</p>
</div><p>The new patents are summarized as follows:</p>
<div class="lb-trans"><p>新专利总结如下：</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Issued</strong><br/><strong>Patent #</strong></td>
<td><strong>Patent Certificate Grant Date</strong></td>
<td><strong>Patent</strong><br/><strong>Family</strong></td>
</tr>
<tr>
<td>AU 2024202475</td>
<td>July 24, 2025</td>
<td>#24 Compositions and Methods for Treating Epilepsy</td>
</tr>
<tr>
<td>US 12,397,042</td>
<td>August 26, 2025</td>
<td>#27 Compositions and Methods for Treating Diabetes</td>
</tr>
<tr>
<td>EP 3858364</td>
<td>September 17, 2025</td>
<td>#1 Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof</td>
</tr>
<tr>
<td>AU 2023200736</td>
<td>October 2, 2025</td>
<td>#18 Compositions and Methods for Enhanced Delivery of Antiviral Agents</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>已授予</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>专利号</strong></td>
<td><strong>专利证书授予日期</strong></td>
<td><strong>专利</strong></td>
</tr>
<tr>
<td><strong>家族</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AU 2024202475</td>
<td>2025 年 7 月 24 日</td>
<td>#24 治疗癫痫的组合物和方法</td>
</tr>
<tr>
<td>US 12,397,042</td>
<td>2025 年 8 月 26 日</td>
<td>#27 治疗糖尿病的组合物和方法</td>
</tr>
<tr>
<td>EP 3858364</td>
<td>2025 年 9 月 17 日</td>
<td>#1 含有脂溶性活性成分的食品和饮料组合物及其使用方法</td>
</tr>
<tr>
<td>AU 2023200736</td>
<td>2025 年 10 月 2 日</td>
<td>#18 增强抗病毒剂递送的组合物和方法</td>
</tr>
</tbody>
</table>
</div><p>In summary, the proceeds from the recent financing provide Lexaria with the opportunity to enhance our corporate business development and strategic R&amp;D programs for 2026, as well as to continue to broaden and strengthen our patent portfolio. Together, these initiatives are being pursued to give Lexaria additional &#34;shots on goal&#34; and opportunities to build shareholder value.</p>
<div class="lb-trans"><p>总之，最近融资的收益为 Lexaria 提供了增强我们 2026 年企业业务发展和战略研发项目的机会，以及继续扩展和加强我们的专利组合。这些举措旨在为 Lexaria 提供更多的 “进攻机会” 和提升股东价值的机会。</p>
</div><p><strong>About Lexaria Bioscience Corp. &amp; DehydraTECH</strong></p>
<div class="lb-trans"><p><strong>关于 Lexaria Bioscience Corp.及 DehydraTECH</strong></p>
</div><p>DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 54 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.</p>
<div class="lb-trans"><p>DehydraTECH™是 Lexaria 的专利药物递送配方和处理平台技术，改善了各种药物通过口服递送进入血液的方式。DehydraTECH 已多次证明能够提高生物吸收率、减少副作用，并更有效地穿越血脑屏障递送某些药物。Lexaria 运营着一个获得许可的内部研究实验室，并拥有 54 项已授予的专利和其他正在全球申请的专利的强大知识产权组合。有关更多信息，请访问 www.lexariabioscience.com。</p>
</div><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警告</strong></p>
</div><p>This press release includes forward-looking statements as such term is defined under applicable securities laws. These statements may be identified by words such as &#34;anticipate,&#34; &#34;if,&#34; &#34;believe,&#34; &#34;plan,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;could,&#34; &#34;should,&#34; &#34;will,&#34; and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering, the Company's anticipated 2026 R&amp;D and business development plans, and the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&amp;D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p>
<div class="lb-trans"><p>本新闻稿包含根据适用证券法定义的前瞻性声明。这些声明可能通过诸如 “预期”、“如果”、“相信”、“计划”、“估计”、“期望”、“打算”、“可能”、“能够”、“应该”、“将会” 等类似词语来识别。本新闻稿中的前瞻性声明包括但不限于公司关于拟定用途的声明，涉及融资所得的使用、公司预期的 2026 年研发和业务发展计划，以及公司开展研究计划、获得监管批准或补助，或从任何研究或研究中获得积极效果或结果的能力。这些前瞻性声明是基于当前信息反映公司最佳判断的估计，涉及多种风险和不确定性，无法保证公司将实际实现这些前瞻性声明中披露的计划、意图或期望。因此，您不应对这些前瞻性声明过度依赖。可能导致实际结果与公司估计结果存在重大差异的因素包括但不限于市场及其他条件、政府监管和监管批准、管理和维持增长、负面宣传的影响、诉讼、竞争、科学发现、专利申请和批准过程、使用 DehydraTECH 技术的产品测试或使用可能产生的潜在不利影响、公司维持现有合作关系并实现其利益的能力、与疫情相关或其他原因导致的计划研发的延迟或取消，以及公司在其公开公告和定期向美国证券交易委员会 EDGAR 提交的文件中不时可能识别的其他因素。公司仅为读者提供第三方网站的链接，且对第三方网站信息的全面性、准确性或及时性不承担任何责任。无法保证 Lexaria 所设想的专利及专利申请技术的任何用途、益处或优势将以任何方式或部分实现。本声明中的任何内容均未经过食品药品监督管理局（FDA）的评估。与 Lexaria 相关的产品并不旨在诊断、治疗、治愈或预防任何疾病。本声明中包含的任何前瞻性声明仅在本声明日期有效，公司明确不承担更新本声明中包含的任何前瞻性声明或第三方网站链接的义务，无论是由于任何新信息、未来事件、情况变化或其他原因，法律另有要求的情况除外。</p>
</div><p><strong>INVESTOR CONTACT:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p><strong>George Jurcic - Head of Investor Relations</strong></p>
<div class="lb-trans"><p><strong>George Jurcic - 投资者关系负责人</strong></p>
</div><p>ir@lexariabioscience.com</p>
<div class="lb-trans"><p>ir@lexariabioscience.com</p>
</div><p>Phone: 250-765-6424, ext. 202</p>
<div class="lb-trans"><p>电话：250-765-6424，分机 202</p>
</div><p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p>
<div class="lb-trans"><p><strong>来源：</strong> Lexaria Bioscience Corp.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTA4NDg4Mg" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1084882"/></p>

Lexaria Bioscience Corp. 提供战略更新 | LEXX 股票新闻